Zoledronic acid (Z) as palliative treatment in cancer patients with bone metastases: Interim results of a prospective, open-label trial
Albrecht Kretzschmar(Roche (Switzerland)), Gerhard Ehninger(University Hospital Carl Gustav Carus), Manfred Kindler(Praxis), H. F. Hinrichs(Klinikum Oldenburg), S-E. Al-Batran(Krankenhaus Nordwest), A. Kirner(Klinikum Oldenburg), Theodore L. Steck(University of Illinois Chicago), U. Haus(Klinikum Oldenburg), H.J. Illiger(Klinikum Oldenburg), Thomas Wiegel(University Hospital Ulm)
Cited by 2
Related Papers
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a <i>FLT3</i> Mutation
|New England Journal of Medicine|2017|2.2k
Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia
|New England Journal of Medicine|2013|1.6k
Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer – A randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)
|European Journal of Cancer|2011|615